Volume 11,Issue 3
The Effect of Liraglutide on Inflammatory Factors and Neurological Prognosis in Patients with Acute Cerebral Infarction Complicated with Type 2 Diabetes Mellitus
Objective: To investigate the effects of liraglutide on blood glucose reduction, inflammatory factor inhibition, vascular endothelial function improvement, and neurological function in patients with acute cerebral infarction (ACI) complicated with type 2 diabetes mellitus (T2DM). Methods: A total of 100 patients with ACI complicated with T2DM admitted to Tangshan People’s Hospital from June 2022 to June 2025 were randomly divided into the liraglutide group and the control group, with 50 cases in each group. Both groups received routine treatment for the acute phase of cerebral infarction. On this basis, the control group was treated with insulin aspart and insulin glargine to control blood glucose, while the liraglutide group was treated with liraglutide combined with insulin glargine. Both groups were treated continuously for 3 months. Results: After treatment, the serum levels of tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) in the liraglutide group were significantly lower than those in the control group. The liraglutide group also reduced endothelin-1 (ET-1) levels and increased nitric oxide (NO) levels. Additionally, the National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin Scale (mRS) score were significantly lower in the liraglutide group compared to the control group, with a higher total clinical effectiveness rate. Conclusion: Liraglutide improves neurological prognosis in patients with ACI complicated with T2DM by strengthening blood glucose reduction, alleviating inflammatory responses, and improving vascular endothelial function.
[1] Zhao L, Liu X, Xing Y, 2022, The Effect of Liraglutide in the Treatment of Patients with Coronary Heart Disease. Inner Mongolia Medical Journal, 54(6): 704–706.
[2] Park B, Bakbak E, Teoh H, 2024, GLP-1 Receptor Agonists and Atherosclerosis Protection: The Vascular Endothelium Takes Center Stage. Am J Physiol Heart Circ Physiol, 326(5): H1159–H1176.
[3] Seufert J, Gallwitz B, 2014, The Extra-Pancreatic Effects of GLP-1 Receptor Agonists: A Focus on the Cardiovascular, Gastrointestinal and Central Nervous Systems. Diabetes Obes Metab, 16(8): 673–688.
[4] Marlet IR, Ölmestig JNE, Vilsbøll T, 2018, Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischaemic Stroke: A Systematic Review Based on Pre-Clinical Studies. Basic Clin Pharmacol Toxicol, 122(6): 559–569.
[5] Guan JF, An LL, Han JQ, et al., 2022, Liraglutide Improves Cerebral Ischemic Injury in Diabetic Rats by Regulating Microglia/Macrophage Polarization Through NOX2. Journal of Army Medical University, 44(11): 1136–1142.
[6] Bu Y, Zhang S, Qian XD, et al., 2022, Effects of Liraglutide on Insulin-Like Growth Factor Binding Protein-3 and Angiogenesis in Brain Tissue of Diabetic Rats with Cerebral Infarction. Chinese Journal of Gerontology, 42(18): 4495–4500.
[7] Wupo W, Deng CH, Li WJ, et al., 2021, Liraglutide Alleviates Cerebral Ischemic Injury in Diabetic Rats by Downregulating NF-κB and Related Inflammatory Factors. International Journal of Laboratory Medicine, 42(17): 2105–2108+2112.
[8] Yuan YM, Song Y, Pei G, et al., 2024, Correlation Between Serum Pro-BDNF and Inflammatory Factors and Clinical Prognosis in Patients with Acute Cerebral Infarction. China Journal of Practical Nervous Diseases, 27(5): 595–599.
[9] Ma XW, Feng WX, Wang LZ, et al., 2023, Changes of Serum IL-6, TNF-α, hs-CRP and MMP-9 in Patients with Different Subtypes of Acute Cerebral Infarction. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 21(15): 2870–2873.
[10] Xu MR, Zhang QH, Chen MW, et al., 2015, Effect of Liraglutide on Peripheral Blood Endothelin-1 and Nitric Oxide Levels in Newly Diagnosed Type 2 Diabetes Mellitus Patients. Chinese Journal of Diabetes, 23(12): 5.
[11] Tong Y, Chen RJ, Chen Y, et al., 2024, Effect of Liraglutide on Blood Glucose Fluctuation, Blood Lipids and Vascular Endothelial Function Indicators in Elderly Patients with Type 2 Diabetes Mellitus. Diabetes New World, 27(2): 24–27.